US-UK trade deal could cause 229,000 excess deaths as NHS diverts billions to new medicines

More than 200,000 excess deaths could result from a US-UK trade deal that forces the NHS to divert billions of pounds from essential services to pay for new medicines, analysis has found. The deal, agreed in December, will require the health service to redirect approximately £45bn – a sum doctors' unions say will cut deeply into frontline care. Ministers have defended the agreement as a way to help British drug exports avoid US tariffs and to give patients access to vital medication. But critics accuse the Labour party of caving into pressure from Donald Trump, with the Guardian's Aditya Chakrabortty warning that the cost in lives could be catastrophic. The analysis, presented by Lucy Hough on the Guardian's Today in Focus podcast, estimates that 229,000 potentially preventable deaths will occur as a result of the diversion. The figure comes from a doctors' union assessment that the deal prioritises pharmaceutical company profits over patient care. The deal was struck by the Labour government in the face of threats from the Trump administration to impose tariffs on British goods. While ministers argue that it protects jobs in the UK's pharmaceutical sector, opponents say it sacrifices the founding principle of the NHS – that healthcare is free at the point of use. The £45bn diversion will hit services such as cancer treatment, mental health support, and emergency care, the union warned. The controversy has reignited debate over the long-term sustainability of the health service and the cost of international trade agreements. With the 229,000 excess deaths figure becoming a rallying cry for campaigners, the government faces growing pressure to explain how it will mitigate the impact. The full scale of the consequences will depend on how the diverted funds are managed – but the analysis leaves little doubt that the trade deal comes at a human cost.